Table 3 Determinants of patient-physician discordance
Discordant patients (152/208) | Concordant patients (56/208) | p value | |
|---|---|---|---|
Median age at enrollment (years) (IQR) | 48 (39–56) | 44.5 (37–50) | p = 0.031 |
Median disease duration (years) (IQR) | 16.5 (7.75–22.25) | 13.5 (5–19) | ns |
Median SLICC-DI (IQR) | 0 (0–1) | 1 (0–2) | ns |
Ongoing joint involvement (% of patients) | 10.5% | 0 | p = 0.012 |
Past joint involvement (% of patients) | 70.9% | 55.3% | p = 0.036 |
GC therapy (% of patients) | 50% | 28.6% | p = 0.006 |
Median GC daily dose (mg methylprednisolone) (IQR) | 0 (0–2) | 1 (0–4) | p = 0.031 |
Fibromyalgia (% of patients) | 15.8% | 1.8% | p = 0.006 |
PCS (mean ± SD) | 54.7 ± 14.1 | 65.8 ± 20.4 | p < 0.0001 |
MCS (mean ± SD) | 54 ± 14.5 | 64.3 ± 17.7 | p < 0.0001 |
LIT (mean ± SD) | 28.4 ± 20.4 | 14 ± 16.8 | p < 0.0001 |
FACIT (mean ± SD) | 35.3 ± 10.1 | 47.3 ± 3.6 | p < 0.0001 |